找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia; W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V

[復(fù)制鏈接]
查看: 43489|回復(fù): 38
樓主
發(fā)表于 2025-3-21 17:27:44 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia
編輯W. Hiddemann,R. Mertelsmann
視頻videohttp://file.papertrans.cn/666/665209/665209.mp4
圖書封面Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia;  W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V
描述Since the introduction of new anthracycline derivatives and anthrachi- none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig- nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys- plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate- dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable
出版日期Conference proceedings 1990
關(guān)鍵詞Aclacinomycin A; Akute Leuk?mie; Myelodysplast; Onkologie; Syndrom
版次1
doihttps://doi.org/10.1007/978-3-642-75720-4
isbn_softcover978-3-540-52613-1
isbn_ebook978-3-642-75720-4
copyrightSpringer-Verlag Berlin Heidelberg 1990
The information of publication is updating

書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影響因子(影響力)




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影響因子(影響力)學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia網(wǎng)絡(luò)公開(kāi)度




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引頻次




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引頻次學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia讀者反饋




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:52:19 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:41:41 | 只看該作者
地板
發(fā)表于 2025-3-22 07:42:53 | 只看該作者
Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute or 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m. twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had
5#
發(fā)表于 2025-3-22 12:13:43 | 只看該作者
6#
發(fā)表于 2025-3-22 13:22:44 | 只看該作者
7#
發(fā)表于 2025-3-22 20:01:07 | 只看該作者
8#
發(fā)表于 2025-3-22 23:41:36 | 只看該作者
9#
發(fā)表于 2025-3-23 04:16:21 | 只看該作者
10#
發(fā)表于 2025-3-23 07:54:00 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-18 17:48
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
水富县| 剑河县| 东山县| 西安市| 贵南县| 阿拉尔市| 永嘉县| 嘉善县| 团风县| 会泽县| 依兰县| 留坝县| 金溪县| 新竹市| 界首市| 武乡县| 大化| 利辛县| 博爱县| 大理市| 汾阳市| 马公市| 伊春市| 乐都县| 兴海县| 都兰县| 田东县| 中卫市| 丹江口市| 青海省| 丹棱县| 抚宁县| 鹰潭市| 沙洋县| 江北区| 碌曲县| 云浮市| 郯城县| 固始县| 郓城县| 宣恩县|